Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re Emergent Biosolutions Inc. Securities Litigation
Case Number:
8:21-cv-00955
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Brown Goldstein
- Cohen Milstein
- Dorsey & Whitney
- Goldman & Minton
- Keller Postman
- Miles & Stockbridge
- Miller & Chevalier
- Murphy Anderson PLLC
- Murphy Falcon
- Pomerantz LLP
- Saxena White
- Silverman Thompson
- WilmerHale
Companies
Sectors & Industries:
-
February 27, 2025
$40M Deal OK'd For Suit Over Emergent Vax Flub
A Maryland federal judge approved a $40 million settlement between Emergent BioSolutions Inc. and a class of investors claiming that it misled them about its ability to meet the demands of two high-profile contracts to produce components of COVID-19 vaccines, leading the stock price to tumble after production deficiencies were discovered.
-
September 13, 2024
Emergent BioSolutions Pays $40M To Settle COVID Vax Suit
Emergent BioSolutions has agreed to pay $40 million to settle a consolidated class action alleging it misled investors about how prepared it was to handle two high-profile deals to manufacture COVID-19 vaccines.
-
September 05, 2023
Emergent Gets Investor Suit Over COVID Vaccine Trimmed
A Maryland federal judge trimmed a consolidated class action claiming that Emergent BioSolutions Inc. misled investors about how prepared it was to handle two high-profile deals to manufacture COVID-19 vaccines, ruling that the investors' fraud claims relating to past earning statements and internal controls can be dismissed.
-
June 21, 2021
Entwistle, Wolf Haldenstein Vie To Rep Emergent Investors
Entwistle & Cappucci LLP and Wolf Haldenstein Adler Freeman & Herz LLP are competing in Maryland federal court to represent a proposed class of investors in a consolidated action claiming that biopharmaceutical company Emergent BioSolutions Inc. misled the public about how prepared it was to handle a pair of high-profile deals to manufacture COVID-19 vaccines.